The methods for handling missing data in clinical trials influence sample size requirements

Journal of Clinical Epidemiology

Volumn 57, Issue 5, 2004, Pages 447-453

  Auleley, Guy Robert ^a   Giraudeau, Bruno ^b   Baron, Gabriel ^c   Maillefert, Jean Francis ^a,d   Dougados, Maxime ^a   Ravaud, Philippe ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d HÔPITAL DU BOCAGE   (France)

Author keywords

Disease modifying osteoarthritis drugs; Hip osteoarthritis; Missing values; Sample size; Structural outcome measures; Study duration

Indexed keywords

ANTIRHEUMATIC AGENT;

ADULT; AGED; ARTICLE; CALCULATION; CONTROLLED STUDY; DISEASE COURSE; DRUG SCREENING; EXPERIMENTAL DESIGN; FEMALE; HIP OSTEOARTHRITIS; HUMAN; INFORMATION PROCESSING; JOINT CAVITY; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PATIENT; POPULATION SIZE; PRIORITY JOURNAL; SAMPLING; TECHNIQUE; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME;

EID: 2942657055     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2003.09.012     Document Type: Article

References (34)

1. Kelsey J.L., Hochberg M.C. Epidemiology of chronic musculoskeletal disorders. Annu Rev Public Health. 9:1988;379-401
2. Altman R.D., Howell D.S. Disease-modifying osteoarthritis drugs. Brandt K.D., Doherty M., Lohmander L.S. Osteoarthritis. 1998;417-428 Oxford University Press, New York
3. Chard J., Dieppe P. Glucosamine for osteoarthritis: magic, hype or confusion? It's probably safe but there's no good evidence that it works. Lancet. 322:2001;1439-1440
4. Pavelká K., Gatterova J., Gollerova V., Urbanova Z., Sedlackova M., Altman R.D. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthrits Cartilage. 8:2000;335-342
5. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., Giacovelli G., Henrotin Y., Dacre J.E., Gossett C. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 357:2001;251-256
6. Altman R., Brandt K., Hochberg M., Moskovitz R. Recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis: Design and conduct of clinical trials in patients with osteoarthritis. Osteoarthritis Cartilage. 4:1996;217-243
7. Bellamy N., Kirwan J., Boers J., Brooks P., Strand V., Tugwell P., Altman R., Brandt K., Dougados M., Lequesne M. Recommendations for a core set of outcome measures for the future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 24:1997;799-802
8. Group for the Respect of Ethics and Excellence in Science (GREES). Osteoarthritis section. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis. 55:1996;552-557
9. Lequesne M., Brandt K., Bellamy N., Moskowitz R., Menkes C.J., Pelletier J.-P. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol. 21:(Suppl 41):1994;65-73
10. Dougados M., Gueguen A., Nguyen M., Berdah L., Lequesne M., Mazieres B., Vignon E. Radiological progression of hip osteoarthritis: definition, risk factors and correlations with clinical status. Ann Rheum Dis. 55:1996;356-362
11. Ravaud P.h., Giraudeau B., Auleley G.-R., Drape J.-L., Rousselin B., Paolozzi L., Chastang C.l., Dougados M. Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. Ann Rheum Dis. 57:1998;624-629
12. Dougados M., Gueguen A., Nguyen M., Berdah L., Lequesne M., Mazieres B., Vignon E. Requirement for total hip arthroplasty: an outcome measure of hip osteoarthritis? J Rheumatol. 26:1999;855-861
13. Bellamy N. Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development. Osteoarthritis Cartilage. 7:1999;424-426
14. Bellamy N., Carette S., Ford P.M., Kean W.F., LeRiche N.G.H., Lussier A., Wells G.A., Campbell J. Osteoarthritis antirheumatic drug trials I. Effects of standardization procedures on observer dependent outcome measures. J Rheumatol. 19:1992;436-443
15. Mazzuca S.A., Brandt K.D., Katz B.P. Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis? Osteoarthritis Cartilage. 5:1997;217-226
16. Mazzuca S., Brandt K.D. Plain radiography as an outcome measure in clinical trials involving patients with knee osteoarthritis. Rheum Dis Clin North Am. 25:1999;467-480
17. Altman R., Alarcon G., Appelrouth D., Bloch D., Borenstein D., Brandt K., Brown C., Cooke D.W., Feldman D. The American College of Rheumatology criteria for the classification and reporting of the hip. Arthritis Rheum. 34:1991;505-514
18. Altman R.D. The classification of osteoarthritis. J Rheumatol. 22:(Suppl 53):1995;42-43
19. Lequesne M.G., Mery C., Samson M., Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol. (Suppl 65):1987;85-89
20. Kellgren J.H., Lawrence J.S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 16:1957;494-502
21. Goker B., Doughan A.M., Schnitzer T.J., Block J.A. Quantification of progressive joint space narrowing in osteoarthritis of the hip. Longitudinal analysis of the contralateral hip after total hip arthroplasty. Arthritis Rheum. 43:2000;988-994
22. Ledingham J., Dawson S., Preston B., Milligan G., Doherty M. Radiographic progression of hospital referred osteoarthritis of the hip. Ann Rheum Dis. 52:1993;263-267
23. Vinceguerra C., Gueguen A., Revel M., Heuleu J.N., Amor B., Dougados M. Predictors of the need for total hip replacement in patients with osteoarthritis of the hip. Rev Rhum Engl Ed. 62:1995;563-570
24. Machin D., Camplbell M.J., Fayers P.M., Pinol A.P.Y. Sample size tables for clinical studies. 1997;Blackwell, Oxford
25. Freiman J.A., Chalmers T.C., Smith H., Kuebler R.R. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 299:1978;690-694
26. Moher D., Dulberg C.S., Wells G.A. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 272:1994;122-124
27. Bellamy N. Design of clinical trials for evaluation of DMOADs and of new agents for symptomatic treatment of osteoarthritis. Brandt K.D., Doherty M., Lohmander L.S. Osteoarthritis. 1998;531-542 Oxford University Press, New York
28. Bellamy N. Standard deviation tables for sample size calculation in rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and fibromyalgia clinical trials. Bellamy N. Musculoskeletal clinical metrology. 1993;337-357 Kluwer Academic Publishers, Dordrecht
29. Ravaud P., Giraudeau B., Auleley G.-R., Edouard-Noël R., Dougados M., Chastang C.l. Assessing smallest detectable change over time in continuous structural outcome measures: application to radiological change in knee osteoarthritis. J Clin Epidemiol. 52:1999;1225-1230
30. Mallinckrodt C.H., Clark W.S., David S.R. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 11:2001;9-21
31. Zhou X.H., Eckert G.J., Tierney W.M. Multiple imputation in public health research. Stat Med. 20:2001;1541-1549
32. Little R.J.A. Methods for handling missing values in clinical trials. J Rheumatol. 26:1999;1654-1656
33. Streiner D.L. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry. 47:2002;262-266
34. Suissa S. Binary methods for continuous outcomes: a parametric alternative. J Clin Epidemiol. 44:1991;421-428